Navigation Links
Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
Date:1/7/2008

elldex intend to file relevant materials with the SEC, including AVANT's joint registration statement/proxy statement on Form S-4. SHAREHOLDERS OF AVANT ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING AVANT'S PROXY STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents free of charge at the SEC's web site, http://www.sec.gov, and AVANT shareholders will receive information at an appropriate time on how to obtain transaction-related documents for free from AVANT. Such documents are not currently available.

Participants in the Solicitation

The directors and executive officers of AVANT and Celldex may be deemed to be participants in the solicitation of proxies from the holders of AVANT common stock in respect of the proposed transaction. Information about the directors and executive officers of AVANT is set forth in the proxy statement for AVANT's most recent 10-K, which was filed with the SEC on March 16, 2007. Investors may obtain additional information regarding the interest of AVANT and its directors and executive officers, and Celldex and its directors and executive officers in the proposed transaction by reading the proxy statement regarding the acquisition when it becomes available.


'/>"/>
SOURCE Celldex Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... bloggers and influencers across North America ... that melanoma prevention begins with parents-encouraging everyone to create a ... Duff , and parenting author Alyson Schafer are ... Monday to share this poignant video message: Click ... Cornfield Melanoma Fund (DCMF)-producers of the viral video ...
(Date:5/6/2015)... , May 06, 2015 Research and ... the addition of the "Cannulas Market by ... Injector, Infusion, Venous, Microcannula), Material (Plastic, Metal) & ... Forecast to 2020" report to their offering. ... to grow at a CAGR of 5.6% from ...
(Date:5/6/2015)... Maine , May 6, 2015  Membership in ... according to a Healthcare Business Strategy report released ... also known as Medigap or Med Supp plans, ... 31, 2014, a 5.2% increase from 2013. Between ... increased by 551,135 covered lives.  Though UnitedHealth was ...
Breaking Medicine Technology:Celebrities Tweet Their Support of Melanoma Awareness Month and #newfamilyrule 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 3Continued Growth in Med Supp Market for 2014 according to Mark Farrah Associates 2
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) announced ... Highly Selective MEK1/2 Inhibitor is Beneficial in Dextran ... was presented at the,American College of Gastroenterology (ACG) ... provided data from a preclinical study of,RDEA119, the ...
... ,Sosei Group Corporation ("Sosei"; TSE Mothers Index: ... announce results of two Phase II studies,evaluating ... presented at the,annual congress of the European ... data show that NVA237 (glycopyrronium bromide), a ...
Cached Medicine Technology:Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5
(Date:5/6/2015)... MA (PRWEB) May 06, 2015 ... for healthcare professionals and students, announced today that in ... 94% confirmed that use of the clinical decision support ... by the end of 2014, UpToDate users in more ... clinical topics per month, on average. In Germany alone, ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup ... China, has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction ... Anitoa’s handheld qPCR is shown to be capable of ... hepatitis B, C, and E. Coli. This qPCR system ... and over 9 orders of magnitude dynamic range. ...
(Date:5/6/2015)... In March, Dr. Rami K. Batniji ... Masterclass. As Europe’s most exclusive rhinoplasty conference, the attendees ... Dr. Batniji was hand chosen to speak by the President ... Dr. Pietro Palma. , The Milano Masterclass is ... hosts a diverse, multi-national faculty; each considered a rhinoplasty expert ...
(Date:5/6/2015)... Locally owned, Greek olive oil producer and ... week as having one the best Extra Virgin Olive Oils ... Peloponnese region of Greece and known as Laconiko , ... of Medium Olive Oil, which is defined by the competition ... over 700 producer applicants from 25 different countries applying, Laconiko ...
(Date:5/6/2015)... The Alliance for Regenerative Medicine ... and advanced therapies community, today announced the release ... in-depth look at sector trends and metrics from ... report is available online here and ... available here . , Using information provided ...
Breaking Medicine News(10 mins):Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3Health News:California Surgeon Speaks at International Rhinoplasty Conference 2Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 3
... labels to help cut heart disease, according to researchers from ... their arguments in this week's British Medical Journal, say that ... number one killer, estimated to be responsible for almost 50 ... cardiovascular disease is reported to cost the EU economy an ...
... because a staff nurse has refused to send an ambulance to ... had an agonizing pain in her lower abdomen. Hence she called ... could not have an ambulance and had to wait for another ... the GP arrived he just gave her some painkillers. ...
... 35-year-old woman in Madhya Pradesh survived carrying a dead foetus ... Friday at the government hospital at Khargone, 348 km from ... removed from her womb. ,Renubai conceived two years ... the seventh month of her pregnancy, her family members thought ...
... it has received the tentative new drug approval ... anti-HIV treatment. // ,The fixed drug ... Abacavir 300mg Tablets, the company informed the Bombay ... is cost-effective and reduces the threat of resistance ...
... of a bird flu vaccine against the deadly H5N1 variety ... unvaccinated monkeys, by researchers at two universities.// ,According ... University, the results are expected to be known within about ... shed light on numerous aspects of the strain's infection mechanism ...
... Act, celebrating its third anniversary, has reduced secondhand smoke ... a study conducted by RTI International. ,According to ... of Health’s Tobacco Control Program, exposure to secondhand smoke ... in the year following the implementation of the law. ...
Cached Medicine News:Health News:Scientists Push for Labeling of all Fats to Avoid Heart Disease 2Health News:New York’s Secondhand Smoke Exposure Continues to Declin 2
... combining the corrosion resistance of stainless ... of copper, SANYO offers an electro-polished ... and maintenance-free. The sterile environment promotes ... results and the safety of laboratory ...
ArcticTemp Upright Freezer -20C. Quick, even freezing. Heavy duty compressor. Deep door racks. Front gated bottom shelf. Interior light. Locks One year warranty on unit and 5 year warranty on compres...
Undercounter Freezer -25C. White. Front opening freezer. 4 cubic ft capacity. Reversible door. Three slide-out drawers. Extra thick CFC insulation. Front lock. Front indicator lights. Attractive tabl...
... highly accurate portable, waterproof system for pH, mV ... pH results can be obtained when used with ... • This GLP/GMP compliant system includes an RS-232 ... computer. Up to 100 data sets can be ...
Medicine Products: